Treatment pathways for management of severe atopic dermatitis
Research type
Research Study
Full title
An evaluation of the current treatment pathways and associated NHS resource use for the management of uncontrolled moderate-to-severe atopic dermatitis in secondary care
IRAS ID
219212
Contact name
Anthony Bewley
Contact email
Sponsor organisation
Sanofi UK
Duration of Study in the UK
0 years, 8 months, 30 days
Research summary
This is an observational, retrospective, multicentre, descriptive research study. The target patient group will be patients who have been diagnosed with moderate to severe Atopic Dermatitis (AD) a minimum of 36 months before the date of enrolment.
The study will take place in 5 centres in the UK and will recruit 60 to 80 patients. The centres will be secondary/tertiary hospitals.This observational study will collect retrospective information relating to patient characteristics (at start of data collection), treatment(s), clinical outcomes, number of dermatitis flares requiring hospital admission and the patient AD management pathway. This would include not only planned care but unplanned hospital admissions and other points of care in the pathway, including A&E and outpatient visits.
Retrospective data will be collected from patients’ medical records by trained data collectors. All patients will be invited to consent to allow a researcher access to their medical records for the purpose of data collection and only those who consent will be included in the study.REC name
East Midlands - Nottingham 1 Research Ethics Committee
REC reference
17/EM/0143
Date of REC Opinion
19 Apr 2017
REC opinion
Further Information Favourable Opinion